NCT01839734View on ClinicalTrials.gov

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

February 29, 2016

Conditions
HIV
Interventions
DRUG

Lubiprostone

Lubiprostone 24 mcg by mouth (PO) once-daily

Trial Locations (1)

60612

Ruth M. Rothstein CORE Center, Chicago

All Listed Sponsors
lead

Ruth M. Rothstein CORE Center

OTHER

NCT01839734 - Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy | Biotech Hunter | Biotech Hunter